Erectile Dysfunction in Coronary Artery Disease and Heart Failure

[1]  C. Child.  Tip of the Iceberg , 2016 .

[2]  F. Montorsi,et al.  A systematic review of the association between erectile dysfunction and cardiovascular disease. , 2014, European urology.

[3]  J. Kostis,et al.  Pharmacologic Therapy for Erectile Dysfunction and its Interaction With the Cardiovascular System , 2014, Journal of cardiovascular pharmacology and therapeutics.

[4]  E. Loh,et al.  Newly diagnosed major depressive disorder and the risk of erectile dysfunction: A population-based cohort study in Taiwan , 2013, Psychiatry Research.

[5]  H. Putter,et al.  A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice , 2013, Netherlands Heart Journal.

[6]  S. Chrysant.  Effectiveness and Safety of Phosphodiesterase 5 Inhibitors in Patients with Cardiovascular Disease and Hypertension , 2013, Current Hypertension Reports.

[7]  C. Vlachopoulos,et al.  Erectile dysfunction in the cardiovascular patient. , 2013, European heart journal.

[8]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[9]  C. Vlachopoulos,et al.  Plasma total testosterone and incident cardiovascular events in hypertensive patients. , 2013, American journal of hypertension.

[10]  F. Montorsi,et al.  Erectile dysfunction in heart failure patients: a critical reappraisal , 2013, Andrology.

[11]  D. Trivedi,et al.  Can simvastatin improve erectile function and health‐related quality of life in men aged ≥40 years with erectile dysfunction? Results of the Erectile Dysfunction and Statins Trial [ISRCTN66772971] , 2013, BJU international.

[12]  P. Macdonald,et al.  Erectile Dysfunction Severity as a Risk Marker for Cardiovascular Disease Hospitalisation and All-Cause Mortality: A Prospective Cohort Study , 2013, PLoS medicine.

[13]  C. Vlachopoulos,et al.  Prediction of Cardiovascular Events and All-Cause Mortality With Erectile Dysfunction: A Systematic Review and Meta-Analysis of Cohort Studies , 2012, Circulation. Cardiovascular quality and outcomes.

[14]  F. Montorsi,et al.  Erectile dysfunction as a cardiovascular risk factor in patients with diabetes , 2013, Endocrine.

[15]  C. Tschöpe,et al.  Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo , 2012, Basic Research in Cardiology.

[16]  S. Heckbert,et al.  Erectile dysfunction is not independently associated with cardiovascular death: data from the vitamins and lifestyle (VITAL) study. , 2012, The journal of sexual medicine.

[17]  R. Kloner,et al.  The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. , 2012, Mayo Clinic proceedings.

[18]  Sergio Callegari,et al.  Pro-inflammatory genetic profile and familiarity of acute myocardial infarction , 2012, Immunity & Ageing.

[19]  M. Susani,et al.  Is penile atherosclerosis the link between erectile dysfunction and cardiovascular risk? An autopsy study , 2012, International Journal of Impotence Research.

[20]  J. G. Ryan,et al.  Erectile dysfunction and its association with metabolic syndrome and endothelial function among patients with type 2 diabetes mellitus. , 2012, Journal of diabetes and its complications.

[21]  Z. Mo,et al.  The association of smoking and erectile dysfunction: results from the Fangchenggang Area Male Health and Examination Survey (FAMHES). , 2012, Journal of andrology.

[22]  Jamie N. Brown,et al.  Phosphodiesterase Type 5 Inhibitors as Adjunctive Therapy in the Management of Systolic Heart Failure , 2011, The Annals of pharmacotherapy.

[23]  G. Forti,et al.  Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. , 2011, European journal of endocrinology.

[24]  L. Qin,et al.  Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. , 2011, Journal of the American College of Cardiology.

[25]  D. Calhoun,et al.  Aldosterone Blockers (Mineralocorticoid Receptor Antagonism) and Potassium‐Sparing Diuretics , 2011, Journal of clinical hypertension.

[26]  M. Ojeda,et al.  Imbalanced low-grade inflammation and endothelial activation in patients with type 2 diabetes mellitus and erectile dysfunction. , 2011, The journal of sexual medicine.

[27]  A. Abbate,et al.  Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. , 2011, American journal of physiology. Heart and circulatory physiology.

[28]  M. Woodward,et al.  Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial. , 2010, Journal of the American College of Cardiology.

[29]  C. Chu,et al.  Coronary phenotypes in patients with erectile dysfunction and silent ischemic heart disease: a pilot study. , 2010, The journal of sexual medicine.

[30]  C. Vlachopoulos,et al.  Cardiovascular aspects of sexual medicine. , 2010, The journal of sexual medicine.

[31]  S. Yusuf,et al.  Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONT , 2010, Circulation.

[32]  C. Stief,et al.  Anatomy, physiology, and pathophysiology of erectile dysfunction. , 2010, The journal of sexual medicine.

[33]  S. Madersbacher,et al.  Is erectile dysfunction a predictor of cardiovascular events or stroke? A prospective study using a validated questionnaire , 2010, International Journal of Impotence Research.

[34]  F. Veglia,et al.  Erectile dysfunction in heart failure: correlation with severity, exercise performance, comorbidities, and heart failure treatment. , 2009, The journal of sexual medicine.

[35]  V. Gentile,et al.  Effect of propionyl-l-carnitine, l-arginine and nicotinic acid on the efficacy of vardenafil in the treatment of erectile dysfunction in diabetes , 2009, Current medical research and opinion.

[36]  M. Creta,et al.  Androgens and morphologic remodeling at penile and cardiovascular levels: a common piece in complicated puzzles? , 2009, European urology.

[37]  R. Kloner,et al.  Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors , 2009, International Journal of Impotence Research.

[38]  L. Lönn,et al.  Hydrochlorothiazide, but not Candesartan, Aggravates Insulin Resistance and Causes Visceral and Hepatic Fat Accumulation: The Mechanisms for the Diabetes Preventing Effect of Candesartan (MEDICA) Study , 2008, Hypertension.

[39]  M. Böhm,et al.  Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome , 2008, International Journal of Impotence Research.

[40]  R. Webb,et al.  Cigarette smoking and erectile dysfunction: focus on NO bioavailability and ROS generation. , 2008, The journal of sexual medicine.

[41]  C. Gazzaruso,et al.  Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. , 2008, Journal of the American College of Cardiology.

[42]  A. Kong,et al.  Erectile dysfunction predicts coronary heart disease in type 2 diabetes. , 2008, Journal of the American College of Cardiology.

[43]  M. Başar,et al.  Effects of statin treatment on serum sex steroids levels and autonomic and erectile function. , 2008, Urology.

[44]  E. Jaimes,et al.  Thiazide diuretics, endothelial function, and vascular oxidative stress , 2008, Journal of hypertension.

[45]  A. Bank,et al.  Erectile dysfunction as a harbinger for increased cardiometabolic risk , 2008, International Journal of Impotence Research.

[46]  Erasmus Mc,et al.  Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study , 2008, International Journal of Impotence Research.

[47]  M. Dowsett,et al.  Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men: European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study , 2007, Circulation.

[48]  C. Vlachopoulos,et al.  Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links. , 2007, European urology.

[49]  I. Goldstein,et al.  Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. , 2007, European urology.

[50]  R. Schwinger,et al.  NITRIC OXIDE, ERECTILE DYSFUNCTION AND BETA‐BLOCKER TREATMENT (MR NOED STUDY): BENEFIT OF NEBIVOLOL VERSUS METOPROLOL IN HYPERTENSIVE MEN , 2007, Clinical and experimental pharmacology & physiology.

[51]  G. Lewis,et al.  Sildenafil Improves Exercise Hemodynamics and Oxygen Uptake in Patients With Systolic Heart Failure , 2006, Circulation.

[52]  C. Ozdol,et al.  Erectile dysfunction may predict coronary artery disease: relationship between coronary artery calcium scoring and erectile dysfunction severity , 2007, International Urology and Nephrology.

[53]  J. Floras,et al.  The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure , 2006, European journal of heart failure.

[54]  C. Vlachopoulos,et al.  Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. , 2006, European heart journal.

[55]  F. Montorsi,et al.  Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. , 2006, European heart journal.

[56]  F. Montorsi,et al.  Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. , 2006, European urology.

[57]  A. L. A S T A I,et al.  Erectile dysfunction. , 2006, Harvard men's health watch.

[58]  P. Ganz.  Erectile dysfunction: pathophysiologic mechanisms pointing to underlying cardiovascular disease. , 2005, The American journal of cardiology.

[59]  I. Thompson,et al.  Erectile dysfunction and subsequent cardiovascular disease. , 2005, JAMA.

[60]  V. Kapur,et al.  Why do patients with heart failure suffer from erectile dysfunction? A critical review and suggestions on how to approach this problem , 2005, International Journal of Impotence Research.

[61]  C. Vlachopoulos,et al.  Prevalence of asymptomatic coronary artery disease in men with vasculogenic erectile dysfunction: a prospective angiographic study. , 2005, European urology.

[62]  C. Vlachopoulos,et al.  Effect of sildenafil on cardiac performance in patients with heart failure. , 2005, The American journal of cardiology.

[63]  R. D'amico,et al.  Subclinical Coronary Artery Atherosclerosis in Patients With Erectile Dysfunction , 2005 .

[64]  S. Madersbacher,et al.  Is erectile dysfunction an indicator for increased risk of coronary heart disease and stroke? , 2005, European urology.

[65]  E. Barrett-Connor.  Heart disease risk factors predict erectile dysfunction 25 years later (the Rancho Bernardo Study). , 2004, The American journal of cardiology.

[66]  S. Madersbacher,et al.  Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. , 2005, European urology.

[67]  F. Montorsi,et al.  Common grounds for erectile dysfunction and coronary artery disease , 2004, Current opinion in urology.

[68]  L. Monti,et al.  Nitric-Oxide Mediated Effects of Transdermal Capsaicin Patches on the Ischemic Threshold in Patients with Stable Coronary Disease , 2004, Journal of cardiovascular pharmacology.

[69]  A. Guay,et al.  Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. , 2004, The Journal of urology.

[70]  S. Necozione,et al.  Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage. , 2004, The Journal of urology.

[71]  F. Montorsi,et al.  Is erectile dysfunction the "tip of the iceberg" of a systemic vascular disorder? , 2003, European urology.

[72]  G. Mancia,et al.  Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study , 2003, Journal of hypertension.

[73]  F. Montorsi,et al.  Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. , 2003, European urology.

[74]  G. Jackson,et al.  eHEART: www.heartjnl.com , 2003 .

[75]  G. Jackson,et al.  Relation of erectile dysfunction to angiographic coronary artery disease. , 2003, The American journal of cardiology.

[76]  H. Krumholz,et al.  Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. , 2002, JAMA.

[77]  E. Bocchi,et al.  Sildenafil Effects on Exercise, Neurohormonal Activation, and Erectile Dysfunction in Congestive Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Study Followed by a Prospective Treatment for Erectile Dysfunction , 2002, Circulation.

[78]  G. Jackson,et al.  IS ERECTILE DYSFUNCTION A MARKER FOR CARDIOVASCULAR DISEASE? , 2001, International journal of clinical practice.

[79]  S. Homma,et al.  Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. , 2000, Journal of the American College of Cardiology.

[80]  A. Araujo,et al.  Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. , 2000, Preventive medicine.

[81]  G. Schuler,et al.  Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral L-arginine supplementation. , 2000, Journal of the American College of Cardiology.

[82]  S. Gardner,et al.  The Impact of First‐Line Antihypertensive Drugs on Erectile Dysfunction , 1999, Pharmacotherapy.

[83]  S. Kaul,et al.  Writing Group Members , 2022 .

[84]  S. Kaul,et al.  ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. , 1999, Journal of the American College of Cardiology.

[85]  I. Goldstein,et al.  A possible mechanism for alteration of human erectile function by digoxin: inhibition of corpus cavernosum sodium/potassium adenosine triphosphatase activity. , 1998, The Journal of urology.

[86]  R. Morgan,et al.  Does severity of ischemic coronary disease correlate with erectile function? , 1997, International Journal of Impotence Research.

[87]  D. Mann,et al.  Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .